KR102307002B1 - 면역 반응성 향상을 위한 포유류 젖 오스테오폰틴 - Google Patents

면역 반응성 향상을 위한 포유류 젖 오스테오폰틴 Download PDF

Info

Publication number
KR102307002B1
KR102307002B1 KR1020167002892A KR20167002892A KR102307002B1 KR 102307002 B1 KR102307002 B1 KR 102307002B1 KR 1020167002892 A KR1020167002892 A KR 1020167002892A KR 20167002892 A KR20167002892 A KR 20167002892A KR 102307002 B1 KR102307002 B1 KR 102307002B1
Authority
KR
South Korea
Prior art keywords
opn
osteopontin
vaccine
cells
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167002892A
Other languages
English (en)
Korean (ko)
Other versions
KR20160030960A (ko
Inventor
앤 스타우트 크비스트가드
피터 랑보르그 웨지스
샤론 도노반
마르샤 에이치. 모나코 시겔
사라 에스. 콤스톡
Original Assignee
아를라 푸즈 에이엠비에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아를라 푸즈 에이엠비에이 filed Critical 아를라 푸즈 에이엠비에이
Publication of KR20160030960A publication Critical patent/KR20160030960A/ko
Application granted granted Critical
Publication of KR102307002B1 publication Critical patent/KR102307002B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020167002892A 2013-07-05 2014-07-04 면역 반응성 향상을 위한 포유류 젖 오스테오폰틴 Active KR102307002B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843185P 2013-07-05 2013-07-05
US61/843,185 2013-07-05
EP13175267 2013-07-05
EP13175267.7 2013-07-05
PCT/EP2014/064339 WO2015001092A1 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Publications (2)

Publication Number Publication Date
KR20160030960A KR20160030960A (ko) 2016-03-21
KR102307002B1 true KR102307002B1 (ko) 2021-10-05

Family

ID=48740972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167002892A Active KR102307002B1 (ko) 2013-07-05 2014-07-04 면역 반응성 향상을 위한 포유류 젖 오스테오폰틴

Country Status (18)

Country Link
US (3) US9956283B2 (cg-RX-API-DMAC7.html)
EP (1) EP3016673B1 (cg-RX-API-DMAC7.html)
JP (1) JP6509833B2 (cg-RX-API-DMAC7.html)
KR (1) KR102307002B1 (cg-RX-API-DMAC7.html)
CN (1) CN105407910B (cg-RX-API-DMAC7.html)
AU (1) AU2014286123B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016000067B1 (cg-RX-API-DMAC7.html)
CA (1) CA2916821C (cg-RX-API-DMAC7.html)
CL (1) CL2015003803A1 (cg-RX-API-DMAC7.html)
DK (1) DK3016673T3 (cg-RX-API-DMAC7.html)
EA (1) EA034654B1 (cg-RX-API-DMAC7.html)
ES (1) ES2656474T3 (cg-RX-API-DMAC7.html)
MX (1) MX369925B (cg-RX-API-DMAC7.html)
NZ (1) NZ715430A (cg-RX-API-DMAC7.html)
PH (1) PH12015502844B1 (cg-RX-API-DMAC7.html)
PL (1) PL3016673T3 (cg-RX-API-DMAC7.html)
PT (1) PT3016673T (cg-RX-API-DMAC7.html)
WO (1) WO2015001092A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102967831B1 (ko) * 2018-04-25 2026-05-20 헬쓰 앤드 해피니스 (에이치&에이치) 홍콩 리미티드 의약으로 사용하기 위한 오스테오폰틴 및 2'-푸코실락토오스의 조합물
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
CN113424962A (zh) * 2020-09-21 2021-09-24 黑龙江飞鹤乳业有限公司 提高免疫力的营养组分、含有其的食品或保健品及其用途
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases
CN113475720B (zh) * 2021-06-15 2023-07-25 合生元(广州)健康产品有限公司 骨桥蛋白在增加肠道菌群多样性和增加肠道短链脂肪酸含量中的应用
EP4472656A1 (en) * 2022-01-31 2024-12-11 Société des Produits Nestlé S.A. Compositions comprising osteopontin (opn)
CN117337994A (zh) * 2023-10-11 2024-01-05 黑龙江飞鹤乳业有限公司 功能性组合物及该组合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
CA2293492A1 (en) * 1997-06-11 1998-12-17 Martin Berry Cns neuroregenerative compositions and methods of use
CA2370129A1 (en) 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
US7259243B2 (en) 2000-01-07 2007-08-21 Arla Foods Amba Process for isolation of osteopontin from milk
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2003239589A1 (en) * 2002-05-24 2003-12-12 Schering-Plough Ltd. Eta-1 gene and methods for use
ES2444843T3 (es) * 2003-09-18 2014-02-27 Arla Foods Amba Fórmula para lactantes
EP1667537B1 (en) * 2003-09-18 2013-11-06 Arla Foods Amba Infant formula
KR20090123115A (ko) 2008-05-27 2009-12-02 한국생명공학연구원 오스테오폰틴을 유효성분으로 함유하는 자연살해세포분화용 조성물 및 이를 이용한 분화 방법
AU2012222312B2 (en) * 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species
US20150344534A1 (en) * 2011-12-07 2015-12-03 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Also Published As

Publication number Publication date
CL2015003803A1 (es) 2016-08-05
US10772955B2 (en) 2020-09-15
CN105407910A (zh) 2016-03-16
AU2014286123B2 (en) 2019-02-28
MX369925B (es) 2019-11-25
NZ715430A (en) 2022-01-28
CA2916821C (en) 2023-10-03
BR112016000067A2 (cg-RX-API-DMAC7.html) 2017-09-05
EA034654B1 (ru) 2020-03-03
EP3016673A1 (en) 2016-05-11
USRE50281E1 (en) 2025-01-28
EA201690057A1 (ru) 2016-07-29
US20160136268A1 (en) 2016-05-19
DK3016673T3 (da) 2018-01-29
CA2916821A1 (en) 2015-01-08
MX2016000107A (es) 2016-06-07
CN105407910B (zh) 2019-12-03
KR20160030960A (ko) 2016-03-21
ES2656474T3 (es) 2018-02-27
BR112016000067B1 (pt) 2022-08-30
AU2014286123A1 (en) 2016-01-21
PT3016673T (pt) 2018-01-30
JP2016529217A (ja) 2016-09-23
JP6509833B2 (ja) 2019-05-08
PL3016673T3 (pl) 2018-04-30
PH12015502844A1 (en) 2016-03-28
US9956283B2 (en) 2018-05-01
WO2015001092A1 (en) 2015-01-08
PH12015502844B1 (en) 2016-03-28
US20180289798A1 (en) 2018-10-11
EP3016673B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
USRE50281E1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
Langel et al. Stage of gestation at porcine epidemic diarrhea virus infection of pregnant swine impacts maternal immunity and lactogenic immune protection of neonatal suckling piglets
Wen et al. High dose and low dose Lactobacillus acidophilus exerted differential immune modulating effects on T cell immune responses induced by an oral human rotavirus vaccine in gnotobiotic pigs
JP4942831B2 (ja) 抗アレルギー用組成物
Saliganti et al. Feeding probiotic Lactobacillus rhamnosus (MTCC 5897) fermented milk to suckling mothers alleviates ovalbumin-induced allergic sensitisation in mice offspring
HK1217914A1 (zh) 稳定的油产品及其制备方法和提高乳酸杆菌菌株存活的方法
JP2008169198A (ja) 抗アレルギーの乳酸菌
Saliganti et al. Consumption of probiotic Lactobacillus rhamnosus (MTCC: 5897) containing fermented milk plays a key role in development of the immune system in newborn mice during the suckling–weaning transition
US20090221497A1 (en) Immunodynamic complexes and methods for using and preparing such complexes
JP2003518073A (ja) クリプトスポリジウムパルヴァムと他の腸内病原体の抗原を含む組成物およびワクチン
WO2022011271A2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
US20020009429A1 (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
EP2066341B1 (en) Method of eliciting or inducing an immune response
CN114340666A (zh) 环二核苷酸的新用途
Liu et al. Specific immune milk production of cows implanted with antigen-release devices
DHAR IMMUNO-STIMULATORY EFFECT OF LEVAMISOLE HYDRO CHLORIDE AND TRICLABENDAZOLE ON THE IMMUNE RESPONSE OF PESTE DES PETITS RUMINANTS (PPR) VACCINATION IN GOATS
Colditz et al. Humoral and cellular factors affecting the neutrophil response of the locally immunised mammary gland to staphylococcal infection
Lu Effects of supplemental osteopontin on intestinal development and serum antibody responses to rotavirus vaccination in piglets
Shunk Effect of bovine lactoferrin on T lymphocyte cell phenotype and function and the response to vaccination in the neonatal piglet
TW202517283A (zh) 包含源自蜂房哈夫尼菌的脂多糖及卡波姆的免疫增強用組合物
Abd Wahab Investigation of the Coeliac Immunogenicity of Cereal Peptides and Their Quantification Using Monoclonal Antibodies
Järvinen Human milk immunology in relation to the development of cow's milk allergy in the breast-fed
HK1100508B (en) A use of a lactic acid bacterial in preparation for pharmaceuticals for improving breast milk of feeding a baby
HK1166670A (en) A stabilized oil product and its method of preparation and method of increasing survival of a lactic acid bacteria strain

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190627

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201029

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210428

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210629

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210924

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240913

Start annual number: 4

End annual number: 4